Cancer Stem Cells: Biology and Therapeutic Implications

被引:12
作者
Mayani, Hector [1 ]
Chavez-Gonzalez, Antonieta [1 ]
Vazquez-Santillan, Karla [2 ]
Contreras, Jorge [3 ]
Guzman, Monica L. [3 ]
机构
[1] Hosp Oncol, Ctr Med Nacl SXXI, Inst Mexicano Seguro Social Ciudad Mxico, Unidad Invest Enfermedades Oncol, Ciudad De Mexico, Mexico
[2] Inst Nacl Med Genom, Ciudad De Mexico, Mexico
[3] Weill Cornell Med, Div Hematol & Oncol, Dept Med, New York, NY USA
基金
美国国家卫生研究院;
关键词
Cancer; Leukemia; Microenvironment; Stem cells; Tumor; ACUTE MYELOID-LEUKEMIA; TUMOR-INITIATING CELLS; IN-VITRO; KAPPA-B; SIGNALING PATHWAY; CLONAL ORIGIN; SELF-RENEWAL; IDENTIFICATION; BREAST; MARKER;
D O I
10.1016/j.arcmed.2022.11.012
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is well recognized that most cancers derive and progress from transformation and clonal expansion of a single cell that possesses stem cell properties, i.e., self-renewal and multilineage differentiation capacities. Such cancer stem cells (CSCs) are usually present at very low frequencies and possess properties that make them key players in tumor development. Indeed, besides having the ability to initiate tumor growth, CSCs drive tumor progression and metastatic dissemination, are resistant to most cancer drugs, and are responsible for cancer relapse. All of these features make CSCs attractive targets for the development of more effective oncologic treatments. In the present review article, we have summarized recent advances in the biology of CSCs, including their identification through their immunophenotype, and their physiology, both in vivo and in vitro . We have also analyzed some molecular markers that might become targets for developing new therapies aiming at hampering CSCs regeneration and cancer relapse.(c) 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:770 / 784
页数:15
相关论文
共 174 条
[31]   A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms [J].
Cojoc, Monica ;
Maebert, Katrin ;
Muders, Michael H. ;
Dubrovska, Anna .
SEMINARS IN CANCER BIOLOGY, 2015, 31 :16-27
[32]   Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction [J].
Copland, Mhairi ;
Hamilton, Ashley ;
EIrick, Lucy J. ;
Baird, Janet W. ;
Allan, Elaine K. ;
Jordanides, Niove ;
Barow, Martin ;
Mountford, Joanne C. ;
Holyoake, Tessa L. .
BLOOD, 2006, 107 (11) :4532-4539
[33]   Selective elimination of leukemia stem cells: Hitting a moving target [J].
Crews, Leslie A. ;
Jamieson, Catriona H. M. .
CANCER LETTERS, 2013, 338 (01) :15-22
[34]   Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis [J].
Darash-Yahana, M ;
Pikarsky, E ;
Abramovitch, R ;
Zeira, E ;
Pal, B ;
Karplus, R ;
Beider, K ;
Avniel, S ;
Kasem, S ;
Galun, E ;
Peled, A .
FASEB JOURNAL, 2004, 18 (09) :1240-+
[35]   Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia [J].
de Beauchamp, Lucie ;
Himonas, Ekaterini ;
Helgason, G. Vignir .
LEUKEMIA, 2022, 36 (01) :1-12
[36]   Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM [J].
Deng, Zhenling ;
Wu, Yanhong ;
Ma, Wenbo ;
Zhang, Shuren ;
Zhang, Yu-Qian .
BMC IMMUNOLOGY, 2015, 16
[37]   Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success [J].
Desai, Amar ;
Yan, Yan ;
Gerson, Stanton L. .
STEM CELLS TRANSLATIONAL MEDICINE, 2019, 8 (01) :75-81
[38]   Two Hundred Years of Cancer Research [J].
DeVita, Vincent T., Jr. ;
Rosenberg, Steven A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (23) :2207-2214
[39]   Stem cell concepts renew cancer research [J].
Dick, John E. .
BLOOD, 2008, 112 (13) :4793-4807
[40]   Defective In Vitro Growth of Primitive Hematopoietic Cells From Pediatric Patients With Acute Myeloid Leukemia [J].
Dorantes-Acosta, Elisa ;
Chavez-Gonzalez, Antonieta ;
Santos, Jose Ignacio ;
Medina-Sanson, Aurora ;
Mayani, Hector .
PEDIATRIC BLOOD & CANCER, 2008, 51 (06) :741-746